Rational approach to the prescription of anti-rheumatic drugs in rheumatoid arthritis: a product leaflet-based strategy in Italy
C Perricone, A Castellucci, G Cafaro… - Frontiers in …, 2024 - frontiersin.org
The treatment of patients with rheumatoid arthritis (RA) has dramatically changed in the past
30 years. Currently, numerous conventional, biologic, and targeted synthetic DMARDs have …
30 years. Currently, numerous conventional, biologic, and targeted synthetic DMARDs have …
Association of tumor necrosis factor inhibitors with the risk of nontuberculous mycobacterial infection in patients with rheumatoid arthritis: a nationwide cohort study
HJ Park, B Choi, YK Song, YJ Oh, EB Lee… - Journal of Clinical …, 2023 - mdpi.com
Tumor necrosis factor inhibitors (TNFi) are proposed as a risk factor for nontuberculous
mycobacteria (NTM) infection. Limited research investigates NTM infection risk in …
mycobacteria (NTM) infection. Limited research investigates NTM infection risk in …
Role of Recombinant Proteins for Treating Rheumatoid Arthritis
MS Sasani, Y Moradi - Avicenna Journal of Medical …, 2024 - pmc.ncbi.nlm.nih.gov
Rheumatoid Arthritis (RA) is an autoimmune disease and chronic inflammatory disorder that
affects joints and causes inflammation, pain, stiffness, and eventually progressive joint …
affects joints and causes inflammation, pain, stiffness, and eventually progressive joint …
[HTML][HTML] Autoimmune Hemolytic Anemia From Tofacitinib Use in a Patient With Ulcerative Colitis
E Zisman, R Bashir-Hamidu… - ACG Case Reports …, 2024 - journals.lww.com
Tofacitinib is a Janus kinase inhibitor commonly used in the management of rheumatoid
arthritis and moderate-to-severe ulcerative colitis. Anemia is a rare side effect of this …
arthritis and moderate-to-severe ulcerative colitis. Anemia is a rare side effect of this …